Introduction
Nutrient supplementation as add-on therapy in rheumatoid arthritis (RA) has witnessed a resurgence of scientific interest due to preclinical and clinical studies on supplementation with polyunsaturated fatty acids (PUFA) or micronutrients.
Initial studies, demonstrating the beneficial effects of dietary fatty acids, made use of fish oils, which contain the omega-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). When supplemented, these lipids compete with arachidonic acid (AA) for incorporation in cellular membranes, resulting in decreased synthesis of specific leukotrienes and prostaglandins (Kremer, 2000) . Furthermore, downmodulatory effects on proinflammatory cytokines have been described. Similar clinical results have been published with the omega-6 fatty acid gamma-linolenic acid (GLA), isolated from certain plant and seed oils (Zurier et al, 1996; Johnson et al, 1997; Belch & Hill, 2000) . Administration of GLA leads to an increased incorporation of its metabolite dihomogammalinolenic acid (DGLA) in cell membranes, thus blocking the metabolism of AA and changing the balance of lipid mediators towards the production of lesspotent eicosanoids. Several clinical studies in RA patients have demonstrated modest but reproducable beneficial effects on the joint tenderness of supplements with EPA þ DHA at doses of 2.3-7.1 g per day (Cleland et al, 2003) . Perhaps, due to the high number of capsules needed to achieve clinical effects combined with their fishy aftertaste, however, nutritional supplements with PUFA have not received the same status as conventional antiphlogistic and analgesic drugs in the management of RA (Sköldstam et al, 1992) .
Micronutrient supplementation also has been propagated for its potential benefit in RA, based on the low antioxidant status in RA patients as compared to healthy controls, the role of chronic oxidative stress in functional hyporesponsiveness of synovial T lymphocytes and the effects of reactive oxygen species (ROS) in cartilage degradation, inflammation and cell signaling (Lunec et al, 1981; Burkhardt et al, 1986; Jikimoto et al, 2002; Taysi et al, 2002) . Additionally, dietary intake of several micronutrients has been reported to be inadequate in RA patients (Stone et al, 1997) . In animal models, high doses of vitamin C, vitamin E and N-acetyl-cysteine had antiarthritic effects related to their antioxidative potential (KheirEldin et al, 1992; Sakai et al, 1999; Tsuji et al, 1999) . Other candidate antioxidants have been identified with potential benefit, including selenium, zinc, manganese, niacinamide, bioflavonoids and b-carotene. Nevertheless, clinical trials with antioxidants in RA patients have been disappointing. A randomized double-blind comparison of high-dose vitamin E (1200 mg daily), the most powerful naturally occurring lipid-soluble antioxidant, did not show any anti-inflammatory effect as compared to placebo (Edmonds et al, 1997) . Two placebo-controlled trials with selenium-enriched yeast (200 and 156 mg/day) did not result in detectable clinical benefit (Tarp et al, 1985; Peretz et al, 2001) .
Given the lack of evidence to date demonstrating the antiarthritic effects of supplementation with a single antioxidant, it has been suggested that combination of several such nutrients might be efficacious (Darlington & Stone, 2001; Calder & Kew, 2002) . We therefore developed a liquid nutritional supplement as a vehicle to deliver supplementary concentrations of EPA, GLA and selected micronutrients, to investigate its clinical and biochemical effects in a prospective, double-blind, placebo-controlled, parallel group trial in patients with active RA.
Subjects and methods

Patients
In all, 66 patients with an established diagnosis of RA enrolled in a single center study (outpatient clinic LUMC) between August 2000 and September 2001. The study was approved by the Medical Ethical Committee and informed consent was obtained from all patients. All had active disease defined as six or more tender or swollen joints, morning stiffness 41 h, or erythrocyte sedimentation rate (ESR) 425 mm/h. Concurrent treatment for RA with corticosteroids and/or disease-modifying antirheumatic drugs was required to be stable for at least 2 months. The exclusion criteria were serious gastrointestinal disease (inflammatory bowel disease, atrophic gastritis, stoma), malignancy, previously established intolerance of fish oil, or regular use of dietary supplements containing fish oil and/or antioxidants.
Study design, randomization and supplementation
This was a placebo-controlled, randomized, double-blind, parallel group intervention trial. Patients were randomly allocated to receive either a liquid nutritional supplement containing PUFA and micronutrients or the placebo, one serving daily for the duration of 4 months. The product was specially produced for this study. The composition of the supplement is shown in Table 1 . Placebo drinks with the Nutrient supplementation in RA PHJ Remans et al same taste, odor and color were produced with water, sweetener (sodiumsaccharine/acesulpham-k), cloudifier, flavor and colorant. Both drink-feeds were provided in 200-ml tetrapacks (white) in two fruit flavors (forest and citrus fruit). The formulae were randomized and the tetrapacks were labeled with the appropriate number before delivery, and the patients were allocated a number on enrollment of the study. Patients and physicians were kept blinded to treatment assignment during the entire study. Patients were instructed to continue their dietary habits. Clinical parameters were evaluated at baseline and after 2 and 4 months by the same observer.
Sample size
The primary outcome parameter was the change of tender joint count. With alpha 0.05 (two-sided), beta 0.8 and allowing for a 20% dropout rate, a sample size of 32 patients per group was needed to detect a difference in tender joint count of 4, given a baseline tender joint count of 13 and standard deviation of 5.1.
Clinical evaluation
Patients participating in the study were evaluated at the start of the trial, and after 2 and 4 months. The clinical evaluation encompassed a 28-tender joint count and a swollen joint count (using a dichotomous scale: 0 ¼ absent, 1¼ present for both counts), patient's visual analogue scale (VAS) for pain, disease activity, general health and physician's VAS for disease activity. Based on these data, the 20% response rate as defined by the American College of Rheumatology (ACR20-response) criteria (Felson et al, 1993) and Disease Activity Score (DAS28, 28-joint count) (Prevoo et al, 1995) were calculated. Grip strength was measured using a manometer (kPa). Duration of morning stiffness (in minutes), anthropometric (weight and height) data and concomitant drugs were recorded. Additionally, patients were asked to document their NSAID intake during the first week after initiation and the week prior to termination in a diary, and to complete a Health Assessment Questionnaire (HAQ) and Arthritis Impact Measurement Scale (AIMS).
Laboratory evaluation
All mentioned variables were performed on fasting blood samples at baseline and after 4 months. Plasma concentrations of fatty acids and vitamins C and E were measured in a subset of both groups (11 supplement þ 12 placebo for fatty acids, and 20 supplement þ 19 placebo for vitamins C and E). The fatty acid composition of the phospholipid fraction was determined in plasma as follows: after total lipid extraction by the method of Bligh and Dyer (1959) , phospholipids were separated from the total lipid fraction by column chromatography using bonded-phase columns (Kaluzny et al, 1985) .
Fatty acids were then methylated with boron trifluoride in methanol according to the method of Morrison and Smith (1964) . The methyl esters (FAME) were separated and quantified by capillary gas chromatography (Shimadzu GC-17A) with a CPSIL88 column (Chrompack; Middelburg, Netherlands).
Vitamins C and E were analyzed by HPLC as previously described (Stump et al, 1984; Liau et al, 1993) .
Data analysis
All statistical analyses were done with the statistical software package STATA 6.0 (StataCorp, College Station, TX, USA). For both treatment groups, Student's paired t-test was applied to assess whether the outcome at 2 and 4 months differed from the baseline value. Unpaired t-tests were used to test whether baseline values and/or the changes from baseline were different between the groups. Statistical significance was accepted at a probability level of 0.05. Correlation analysis was performed in order to assess whether changes after 4 months of treatment were consistent among biochemical parameters.
Results
In all, 66 patients enrolled in the trial: 33 in the placebo group and 33 receiving the nutrient supplement. The two groups did not differ with respect to clinical and demographic variables at baseline, except for a higher age in the experimental group. A total of 11 subjects (17%) dropped out during the 4 months treatment period: three (5%) due to gastro-intestinal intolerance (two in the experimental group, one in the control group), eight (12%) due to lack of efficacy (five in the experimental group and three in the control group). Baseline characteristics of completers in both groups are shown in Table 2 .
In total, 55 patients completed the 4 months of treatment: 29 receiving placebo and 26 the supplement. Changes in clinical parameters are listed in Table 3 . Mean tender joint count, the primary study parameter, did not change significantly between the groups nor within each group. Disease activity as measured with DAS28 deteriorated in both groups after 4 months, but this attained statistical significance only in the control group, but not in the experimental group or between the groups. Two patients receiving the supplement and two receiving placebo achieved an ACR20 response at 4 months. When the individual components of the ACR20 response criteria and DAS28 outcome criteria were analyzed, no significant changes within the groups nor differences in changes between the groups were detected. Functional assessment by means of the AIMS and HAQ questionnaire also showed no changes. No differences in the taking of NSAIDs were found. A statistically significant increase in body weight was detected in the experimental group at 2 months, but the changes in weight and BMI were not significant between the groups. Figure 1 shows the changes in plasma concentrations of the key PUFA. All patients receiving nutrient supplementation had significant increases in the omega-3 PUFA (EPA, DPA, DHA) when compared to baseline. These changes were also significantly higher when compared to changes in the placebo group. The mean concentration of omega-6 PUFA (GLA, DGLA) did not change in either group. Plasma AA concentrations significantly decreased in the patients taking the nutrient supplement, but not in the placebo group. Changes in plasma DAS28 denotes disease activity score, VAS visual analogue scale, HAQ health-assessment questionnaire, AIMS arthritis impact measurement scale.For both treatment groups, Student's paired t-test was applied to assess whether the outcome at 2 and 4 months differed from the baseline value. Unpaired t-tests were used to test whether baseline values and/or the changes from baseline were different between the groups. With statistical significance accepted at a probability level of 0.05, none of the changes reached significance except for the change in body weight in the supplement group at 2 months (P¼0.002).
concentrations of EPA correlated inversely with AA (r À0.66, P¼0.001) and positively with DPA and DHA (r 0.83 for both, Po0.0001), while those of DPA with DHA and GLA with DGLA also significantly correlated (r 0.75, Po0.0001, r 0.59, P¼0.003, respectively). Increases in serum concentrations of vitamin C (mean7s.d. at baseline 51.7725.1, delta mean 6.9728.3; P 0.74) and vitamin E (mean7s.d. at baseline 33.477.5 mM, delta mean 4.376.5; P¼0.015) were observed in the experimental arm, and decreases in the placebo group of vitamin C (mean7s.d. at baseline 42.7721.6 mM, delta mean À3.8715.1; P¼0.98) and vitamin E (mean7s.d. at baseline 34.678.6, delta mean À0.476.3; P¼0.76). The intergroup difference in vitamin E was significant (P¼0.03).
Discussion
This is the first double-blind, placebo-controlled study to investigate the clinical efficacy of a daily nutrient supplementation containing PUFA and micronutrients in RA patients. Based on preclinical data, it was postulated that the combination of these nutrients would produce synergistic or additive effects without compromising safety (Chilton et al, 1993; Venkatraman & Chu, 1999 ). An odorless liquid nutritional supplement was developed as a vehicle to enhance compliance. Compared to placebo, supplementation resulted in significant increases in serum concentrations of EPA, DPA, DHA and vitamin E, and a modest increase in body weight, indicating that compliance was indeed achieved. This was further corroborated by correlations between individual PUFA. However, no statistically significant difference was found in the primary outcome parameter, the change in tender joint counts (TJC), nor in the other clinical parameters measured.
Several factors may have influenced the outcome of our study. First, our trial was designed as a pragmatic trial to evaluate the add-on therapeutic effect of nutrient supplementation in RA patients with persistent disease activity despite antiphlogistic and antirheumatic medication. This may have introduced bias by selection of patients in whom marked improvement of (symptoms of) disease activity is difficult to achieve. The probability to detect significant changes in TJC (but not the other clinical parameters) may have also been compromised because baseline values were lower than anticipated. Second, the metabolism and effects of PUFA and micronutrients may have been affected by continued use of NSAIDs and dietary factors. Recent studies reported that the beneficial effects of EPA are reduced when the diet is high in essential omega-6 PUFA by the intake of margarine and polyunsaturated oil (Cleland et al, 1992; Simopoulos, 2002) . With an average intake of omega n-6 PUFA in a Dutch diet of 12-13 g/day (de Vries et al, 1997) (approximately 10 Â the amount in the supplement), such interaction cannot be ruled out. On the other hand, in most published studies, patient populations did not differ from ours with respect to background medication and diet. Third, the concentrations of EPA, GLA and micronutrients may have been too low, even though marked and significant effects on plasma concentrations of EPA and AA were detected in the present study. Although we did not measure membrane fatty acid levels, changes in plasma fatty acids have been extensively used as surrogate markers. Previous reports demonstrated the efficacy of slightly higher doses of omega-3 PUFA, but not of lower doses than used in our study. One study comparing low-and high-dose omega-3 PUFA (27 mg/kg EPA þ 18 mg/kg DHA vs 54 mg/kg EPA þ 36 mg/kg DHA, respectively) showed equal Nutrient supplementation in RA PHJ Remans et al effectiveness on tender and swollen joint counts, but only effects on other variables in the high-dose group (Kremer et al, 1990) . Another study comparing the daily supplements with either 2.6 g of omega-3 PUFA, 1.3 g omega-3 PUFA plus 3 g olive oil, or 6 g olive oil in patients with active RA only found significant clinical benefit in the first group (Geusens et al, 1994) . GLA has been shown to be clinically effective in RA at doses higher than 0.45 g/day, but the possibility of a dose dependence of these effects could explain the lack of efficacy in our trial. Food technological constraints precluded the use of higher concentrations of PUFA in our supplement. With respect to micronutrients, little is known about the doses needed to induce immunomodulation (Rosenstein & Caldwell, 1999) . Studies with single antioxidants failed to demonstrate a significant clinical effect of high doses of selenium, or vitamin E in RA patients (Tarp et al, 1985; Edmonds et al, 1997; Peretz et al, 2001 ). Although our study was primarily designed to investigate the potential add-on effects of PUFA and micronutrient supplementation on symptoms and disease activity, other beneficial clinical effects cannot be excluded, cardioprotective in particular. RA patients suffer from excessive cardiovascular morbidity and mortality when compared to ageand sex-matched individuals (del Rincon et al, 2001) . Epidemiological and interventional studies have shown the protective effects of fish oil and PUFA on cardiovascular events in various populations, in part through modulation of serum lipids (Kris-Etherton et al, 2002) . Interestingly, a recent study showed the significant effects of supplementation with fish oil-derived PUFA and GLA on circulating plasma lipids and fatty acid profiles in healthy women, estimated to result in a 43% reduction in the risk of myocardial infarction (Laidlaw & Holub, 2003) . Whether these results apply to patients with chronic inflammatory disorders remains to be proven. Extrapolating results from these studies, large-scale clinical trials would be needed to demonstrate the cardioprotective effects in RA.
We conclude that nutritional supplementation with micronutrients and PUFA at the doses tested does not ameliorate signs and symptoms in RA patients. More needs to be learned on the role of antioxidants in chronic inflammatory conditions such as RA, possible interactions (synergistic or antagonistic) between various antioxidants and PUFA, and dose-response relationships.
